Dexcom CEO on strategy for bringing continuous glucose monitoring to type 2 diabetes patients

Dexcom, a leading diabetes technology company, has long aimed to provide continuous glucose monitors (CGMs) to type 2 diabetes patients. Recently, at the American Diabetes Association's conference, the company introduced a software specifically tailored for these patients, including those who do not require insulin. Dexcom's CEO, Kevin Sayer, highlighted the focus on meeting the needs of individuals managing type 2 diabetes without constant insulin management. Continuous glucose monitoring, widely adopted by type 1 diabetes patients dependent on continuous insulin therapy, is now expanding its reach.

Medigy Insights

Dexcom, a prominent diabetes technology company, has persistently pursued the provision of continuous glucose monitors (CGMs) to individuals with type 2 diabetes. During the recent American Diabetes Association's conference, the company unveiled a specialized software catering to this patient population, even encompassing non-insulin-dependent individuals. Emphasizing the importance of addressing the requirements of type 2 diabetes management without constant insulin administration, Dexcom's CEO, Kevin Sayer, highlighted the expansion of continuous glucose monitoring beyond its prevalent usage among type 1 diabetes patients reliant on uninterrupted insulin therapy.

Continue reading at statnews.com

Make faster decisions with community advice

Close The Behavioral Health EMR Gap

The integration of behavioral health into the broader healthcare system necessitates the integration of underlying systems and data. However, these crucial connections have been lacking, largely due …

Posted Jul 10, 2023